{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:09:42Z","timestamp":1769594982273,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70\u2009mg\/m<jats:sup>2<\/jats:sup>) and dexamethasone (once-weekly Kd70 mg\/m<jats:sup>2<\/jats:sup>) improved progression-free survival compared with twice-weekly carfilzomib (27\u2009mg\/m<jats:sup>2<\/jats:sup>) and dexamethasone (twice-weekly Kd27 mg\/m<jats:sup>2<\/jats:sup>) in patients with relapsed and refractory multiple myeloma (RRMM; median, 11.2 versus 7.6 months; hazard ratio [HR]\u2009=\u20090.69; 95% confidence interval, 0.54\u20130.88; <jats:italic>P<\/jats:italic>\u2009=\u20090.0029). Once-weekly dosing also improved response rates and depth of response. We performed a subgroup analysis from A.R.R.O.W. according to age (&lt;65, 65\u201374, or \u226575 years), renal function (creatinine clearance &lt;50, \u226550\u2013&lt;80, or \u226580\u2009mL\/min), number of prior therapies (2 or 3), and bortezomib-refractory status (yes or no). Compared with twice-weekly Kd27 mg\/m<jats:sup>2<\/jats:sup>, once-weekly Kd70 mg\/m<jats:sup>2<\/jats:sup> reduced the risk of progression or death (HR\u2009=\u20090.60\u20130.85) and increased overall response rates in nearly all the examined subgroups, consistent with reports in the overall A.R.R.O.W. population. The safety profiles of once-weekly Kd70 mg\/m<jats:sup>2<\/jats:sup> across subgroups were also generally consistent with those in the overall population. Findings from this subgroup analysis generally demonstrate a favorable benefit\u2013risk profile of once-weekly Kd70 mg\/m<jats:sup>2<\/jats:sup>, further supporting once-weekly carfilzomib dosing as an appropriate treatment option for patients with RRMM, regardless of baseline patient and disease characteristics.<\/jats:p>","DOI":"10.1038\/s41408-020-0300-y","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T18:03:41Z","timestamp":1583777021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Zahlten-Kumeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"300_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"300_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"300_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2017.11.016","volume":"121","author":"G Cook","year":"2018","unstructured":"Cook, G., Zweegman, S., Mateos, M. V., Suzan, F. & Moreau, P. A question of class: treatment options for patients with relapsed and\/or refractory multiple myeloma. Crit. Rev. Oncol. Hematol. 121, 74\u201389 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"300_CR4","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"300_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","volume":"92","author":"D Dingli","year":"2017","unstructured":"Dingli, D. et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin. Proc. 92, 578\u2013598 (2017).","journal-title":"Mayo Clin. Proc."},{"key":"300_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar, S. K. et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. 79, 867\u2013874 (2004).","journal-title":"Mayo Clin. Proc."},{"key":"300_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.13","volume":"7","author":"N Tandon","year":"2017","unstructured":"Tandon, N. et al. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 7, e528 (2017).","journal-title":"Blood Cancer J."},{"key":"300_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou, V. et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk. Lymphoma 48, 337\u2013341 (2007).","journal-title":"Leuk. Lymphoma"},{"key":"300_CR9","first-page":"423","volume":"11","author":"J Willan","year":"2016","unstructured":"Willan, J. et al. Multiple myeloma in the very elderly patient: challenges and solutions. Clin. Interv. Aging 11, 423\u2013435 (2016).","journal-title":"Clin. Interv. Aging"},{"key":"300_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach, J. et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30, 1005\u20131017 (2016).","journal-title":"Leukemia"},{"key":"300_CR11","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1182\/blood.V118.21.5141.5141","volume":"118","author":"H Kim","year":"2011","unstructured":"Kim, H. et al. Efficacy and safety of once-weekly bortezomib infusion in the treatment of relapsed\/refractory multiple myeloma. Blood 118, 5141 (2011).","journal-title":"Blood"},{"key":"300_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cncr.23606","volume":"113","author":"JD Hainsworth","year":"2008","unstructured":"Hainsworth, J. D. et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 113, 765\u2013771 (2008).","journal-title":"Cancer"},{"issue":"12","key":"300_CR13","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","volume":"33","author":"Philippe Moreau","year":"2019","unstructured":"Moreau, P. et al. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m2 vs. twice-weekly 27 mg\/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia https:\/\/doi.org\/10.1038\/s41375-019-0480-2 (2019).","journal-title":"Leukemia"},{"key":"300_CR14","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel, D. S. et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120, 2817\u20132825 (2012).","journal-title":"Blood"},{"key":"300_CR15","unstructured":"KYPROLIS\u00ae. KYPROLIS\u00ae (carfilzomib) [prescribing information] (Onyx Pharmaceuticals, Inc, South San Francisco, CA, 2018)."},{"key":"300_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17, 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"key":"300_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142\u2013152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"300_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel, D. S. et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 36, 728\u2013734 (2018).","journal-title":"J. Clin. Oncol."},{"key":"300_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 18, 1327\u20131337 (2017).","journal-title":"Lancet Oncol."},{"key":"300_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.14549","volume":"177","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br. J. Haematol. 177, 404\u2013413 (2017).","journal-title":"Br. J. Haematol."},{"key":"300_CR21","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1080\/10428194.2017.1298755","volume":"58","author":"H Ludwig","year":"2017","unstructured":"Ludwig, H. et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk. Lymphoma 58, 2501\u20132504 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"300_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.31","volume":"7","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 7, e554 (2017).","journal-title":"Blood Cancer J."},{"key":"300_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/leu.2016.186","volume":"31","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia 31, 115\u2013122 (2017).","journal-title":"Leukemia"},{"key":"300_CR24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau, H. et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128, 1174\u20131180 (2016).","journal-title":"Blood"},{"key":"300_CR25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/leu.2016.390","volume":"31","author":"WJ Chng","year":"2017","unstructured":"Chng, W. J. et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia 31, 1368\u20131374 (2017).","journal-title":"Leukemia"},{"key":"300_CR26","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood-2017-05-786004","volume":"130","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Superior efficacy of carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in multiple myeloma (MM) patients with moderate or serious renal failure: a subgroup analysis of the phase 3 ENDEAVOR study. Blood 130, 1845 (2017).","journal-title":"Blood"},{"key":"300_CR27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau, P. et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 19, 953\u2013964 (2018).","journal-title":"Lancet Oncol."},{"key":"300_CR28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"300_CR29","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"issue":"4 Suppl 2","key":"300_CR30","first-page":"18","volume":"1","author":"L Repetto","year":"2003","unstructured":"Repetto, L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J. Support. Oncol. 1(4 Suppl 2), 18\u201324 (2003).","journal-title":"J. Support. Oncol."},{"key":"300_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1200\/JCO.2001.19.4.1147","volume":"19","author":"R Yancik","year":"2001","unstructured":"Yancik, R., Ganz, P. A., Varricchio, C. G. & Conley, B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J. Clin. Oncol. 19, 1147\u20131151 (2001).","journal-title":"J. Clin. Oncol."},{"key":"300_CR32","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/cam4.1075","volume":"6","author":"Y Qian","year":"2017","unstructured":"Qian, Y. et al. Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States. Cancer Med. 6, 1523\u20131530 (2017).","journal-title":"Cancer Med."},{"key":"300_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.mcna.2004.11.007","volume":"89","author":"S Gabardi","year":"2005","unstructured":"Gabardi, S. & Abramson, S. Drug dosing in chronic kidney disease. Med. Clin. North Am. 89, 649\u2013687 (2005).","journal-title":"Med. Clin. North Am."},{"issue":"Suppl 1","key":"300_CR34","first-page":"5","volume":"4","author":"SE Kurtin","year":"2013","unstructured":"Kurtin, S. E. Relapsed or relapsed\/refractory multiple myeloma. J. Adv. Pract. Oncol. 4(Suppl 1), 5\u201314 (2013).","journal-title":"J. Adv. Pract. Oncol."},{"key":"300_CR35","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","volume":"18","author":"DC Ziogas","year":"2017","unstructured":"Ziogas, D. C., Terpos, E., Kastritis, E. & Dimopoulos, M. A. An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin. Pharmacother. 18, 1883\u20131897 (2017).","journal-title":"Expert Opin. Pharmacother."},{"key":"300_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.13799","volume":"172","author":"E Muchtar","year":"2016","unstructured":"Muchtar, E. et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br. J. Haematol. 172, 89\u201396 (2016).","journal-title":"Br. J. Haematol."},{"key":"300_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon, T. et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131, 301\u2013310 (2018).","journal-title":"Blood"},{"key":"300_CR38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1634\/theoncologist.2017-0440","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte, E. D. et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist 23, 734\u2013739 (2018).","journal-title":"Oncologist"},{"key":"300_CR39","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ctrv.2015.07.005","volume":"41","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos, M. A., Terpos, E., Niesvizky, R. & Palumbo, A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat. Rev. 41, 827\u2013835 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"300_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J. Clin. Oncol. 32, 587\u2013600 (2014).","journal-title":"J. Clin. Oncol."},{"key":"300_CR41","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: multiple myeloma version 2.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf (2019). Accessed 15 October (2019)."},{"key":"300_CR42","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"10","author":"J Mikhael","year":"2019","unstructured":"Mikhael, J. et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. J. Clin. Oncol. 10, 1228\u20131263 (2019).","journal-title":"J. Clin. Oncol."},{"key":"300_CR43","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"300_CR44","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 103, 2088\u20132096 (2018).","journal-title":"Haematologica"},{"key":"300_CR45","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"300_CR46","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer, A. et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103, 2079\u20132087 (2018).","journal-title":"Haematologica"},{"issue":"2","key":"300_CR47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3324\/haematol.2019.217448","volume":"105","author":"Maria-Victoria Mateos","year":"2019","unstructured":"Mateos, M. V. et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica https:\/\/doi.org\/10.3324\/haematol.2019.217448 (2019).","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0300-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:26:41Z","timestamp":1670250401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0300-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0300-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"29 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.D. has received consulting fees and honoraria from Amgen, Bristol-Myers Squibb (BMS), Takeda, Celgene, and Janssen. R.N. has received consulting fees and research funding from Takeda, Celgene, BMS, Amgen, and Janssen. K.W. has received honoraria from Amgen, BMS, Celgene, Janssen, Novartis, and Takeda; consulting fees from Amgen, Adaptive, BMS, Celgene, Janssen, Takeda, Sanofi, and Juno; and research funding from Amgen, Celgene, Sanofi, and Janssen. D.S.S. has received consulting fees from Takeda, Karyopharm, Merck, Celgene, Janssen, BMS, and Amgen; honoraria from Takeda, Karyopharm, Merck, Celgene, Janssen, BMS, Novartis, and Amgen; served on speakers\u2019 bureaus for Takeda, Merck, Celgene, Janssen, BMS, Novartis, and Amgen; and has received research funding from Celgene. R.H. has received consulting fees, honoraria, and research funding from Amgen, Takeda, Celgene, Janssen, AbbVie, Novartis, PharmaMar, and BMS. M.-V.M. has received consulting fees from and served on Board of Directors\/advisory committees for AbbVie, Amgen, GlaxoSmithKline, Takeda, Janssen, and Celgene and honoraria from Amgen, Takeda, Janssen, and Celgene. M.C. has received honoraria from and served on Board of Directors\/advisory committees for AbbVie, BMS, Takeda, GlaxoSmithKline, Adaptive Biotechnologies, Janssen, Celgene, and Amgen and served on speakers\u2019 bureaus for and received research funding from Janssen and Celgene. M.H. and A.Z.-K. are employees of, and own stock in, Amgen. P.M. has received honoraria from, and served on Board of Directors\/advisory committees for, Amgen, Celgene, Janssen, Takeda, and AbbVie and served on speakers\u2019 bureaus for Amgen, Celgene, Janssen, and AbbVie.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}